|12760 High Bluff Drive, Suite 280 , San Diego, CA 92130|
|Fund Manager||Michael Krause|
|Manager Tenure||5 Years 10 Months|
The Counter point Tactical Equity Fund (the Fund ) seeks capital appreciation and preservation.Under normal market conditions,the Fund invests at least 80% of its assets (plus the amount of borrowings,if any) in long and short positions in equity instruments of any market capitalization.Equity instruments include domestic and foreign common stock,preferred stock,depositary receipts,equity swaps (including single-name,index,and basket swaps),options,equity index futures,and other investment companies (such as exchange traded finds ( ETFs ),mutual funds,and closed-end funds) thatinvest in these types of securities.The Fund may hedge exposure to foreign currencies using foreign currency forwards or futures.In managing the Fund,the Fund s adviser, Counter point Mutual Funds,LLC (the Adviser ),employs a strategy that generates returns from two sources: (1) stock selection and (2)tactical market exposure.Stock Selection.The Adviser selects the particular stocks on which to go long and short based on multi-factor quantitative models.The models are based on proprietary research related to economic indicators and investment a nomalies found in peer-reviewed academic journals.An investment anomaly refers to a situation when a security or group of securities performs contrary to the notion of efficient markets,which states that security prices reflect all available information at any point in time.Published papers in academic finance journals have identified more than one hundred investment anomalies.An example of such an anomaly would be the asset growth anomaly where the literature has shown that companies that are more aggressive with spending their capital have worse average stock performance than companies that are more conservative in their capital expenditures.Perfect market efficiency would not yield any market outperformance from investment decisions based on publicly available accounting data such as this.The Fund seeks to target the best performing,recent,and persistent anomalies.The Fund may invest in stocks that provide exposure to a wide variety of anomalies.The Adviser sstrategy may seek to capitalize on many market anomalies at any one time.The Adviser may adjust its model to include newer and more effective anomalies and pare down exposure to older under performing anomalies on a regular basis.The signals from these models indicate which stocks are undervalued and likely to increase in price and which stocks are overvalued and likely to decrease in price.The Adviser takes long positions in the undervalued securities and short positions in the overvalued securities.
|Asset Type||% Of Allocation|
|Total Net Assets||10.94 M|
|Criteria||3 Years||5 Years||10 Years|
|Minimum Initial IRA||$100000|
|Timeframe||Average Annual Current Performance Monthly As Of 08/31/2021||Average Annual Current Performance Quarterly As Of 06/30/2021||Avg Annual Current Performance Monthly As Of 08/31/2021||Avg Annual Current Performance Quarterly As Of 06/30/2021|
|Life Of Fund||
Join the Action Alerts PLUS Community today!
Brooks Automation is selling its chip solutions group and said it would no longer pursue splitting into two companies.
DR Horton said "significant disruptions in the supply chain ... along with tightness in the labor market" will lead to a modestly lower full-year sales forecast.
Colgate-Palmolive stock was upgraded to buy with an $86 price target at Deutsche Bank.
Jim Cramer discusses the market selloff, Evergrande, debt ceiling talks, the upcoming Federal Reserve meeting, Pfizer and more in his latest video interview with TheStreet.
Wynn Resorts faces regulatory uncertainty in Macau, but Morgan Stanley says the casino operator is still 'worth the risk.'
Tesla wants to expand its autonomous-driving effort to help cars make their way through cities, not just highways.
Stocks moving in premarket trading Monday include Pfizer, Netflix, Li Auto, AstraZeneca and Bank of America.
'Lehman moment' or managed failure? Either result has global markets rattled by the impending default of property developer China Evergrande.
What data should corn market watchers seek out in a tight market? A new volatility gauge offers some answers.
"These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency," said Pfizer CEO Albert Bourla.